Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID

Patrick K.A. Kearns,Charles Dixon,Mihaly Badonyi,Kim Lee,Rafal Czapiewski,Olivia Fleming,Prajitha Nadukkandy,Lukas Gerasimivicous,Rinal Sahputra,Bethany Potts,Sam Benton,Jacky Guy,Scott Neilson,Helen Wise,Sara Jenks,Kate Templeton,CIRCO,Christina Dold,Teresa Lambe,Andrew Pollard,Alexander J Mentzer,Julian C Knight,COMBAT,Susanna Dunachie,Paul Klenerman,Eleanor Barnes,Alan Carson,Laura McWhirter,Tracy Hussell,Rennos Fragkoudis,Susan Rosser,David Cavanagh,Graeme Cowan,Madhvi Menon,Joseph A. Marsh,Dirk A. Kleinjan,Nick Gilbert

DOI: https://doi.org/10.1101/2022.07.11.22277368

2024-04-15

Abstract:Even within a single protein, antibody binding can have beneficial, neutral, or harmful effects during the response to infection. Resolving a polyclonal antibody repertoire across a pathogen’s proteome to specific epitopes may therefore explain much of the heterogeneity in susceptibility to infectious disease. However, the three-dimensional nature of antibody-epitope interactions makes the discovery of non-obvious targets challenging. We implemented a novel computational method and synthetic biology pipeline for identifying epitopes that are functionally important in the SARS-CoV-2 proteome and identified an IgM-dominant response to an exposed Membrane protein epitope which to our knowledge is the strongest correlate of severe disease identified to date (adjusted OR 72.14, 95% CI: 9.71 – 1300.15), stronger even than the exponential association of severe disease with age. We also identify persistence (> 2 years) of this IgM response in individuals with longCOVID, and a correlation with fatigue and depression symptom burden. The repetitive arrangement of this epitope and the pattern of isotype class switching is consistent with this being a previously unrecognized T independent antigen. These findings point to a coronavirus host-pathogen interaction characteristic of severe virus driven immune pathology. This epitope is a promising vaccine and therapeutic target as it is highly conserved through SARS-CoV-2 variant evolution in humans to date and in related coronaviruses (e.g. SARS-CoV), showing far less evolutionary plasticity than targets on the Spike protein. This provides a promising biomarker for longCOVID and a target to complement Spike-directed vaccination which could broaden humoral protection from severe or persistent disease or novel coronavirus spillovers.

Infectious Diseases (except HIV/AIDS)